The stream · Daily digest
The stream: Tuesday, November 3, 2026
12 briefs from ClinicalTrials.gov and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 8
-
Thryv Therapeutics announces $30 million financing to launch ASPIRE-HF study
The company secured $30 million Series B financing led by InClin, Inc. to fund the Phase 2a ASPIRE-HF study in heart failure with reduced ejection fraction and QTc prolongation, which opens for enrollment in early 2027. Wave II, a Phase 2/3 study of THRV-1268 in Long QT Syndrome, has completed enrollment of its first efficacy cohort, with data expected in early 2027.
Source: Company press release (PR Newswire), November 3, 2026
-
Xtalks hosts webinar on smarter site selection for early-phase trials
The webinar, scheduled for Tuesday, November 17, 2026 at 11am EST, will explore how early-phase biotech teams can improve enrollment predictability by integrating recruitment into study design and site selection. Speakers include Chris Morris of PPD, Irina Strachkova of Patient First Digital Solutions, and Dr. Lukasz Wiech of Trialmed.
Source: Company press release (PR Newswire), November 3, 2026
-
Hutchmed registers Phase III trial of HMPL-306 in postoperative residual or recurrent grade 2 glioma
The study plans to enroll 210 participants and plans to begin in November 2026, with primary completion projected for March 2032. It is a randomized, double-blind, placebo-controlled multicenter Phase III trial evaluating HMPL-306 tablet safety and efficacy.
Source: ClinicalTrials.gov registry record, November 3, 2026
-
Jiangsu HengRui Medicine registers Phase 3 trial of SHR-3167 vs insulin degludec in type 2 diabetes
The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll an estimated 680 participants and plans to start in November 2026. It is a multicenter, randomized, open-label Phase III trial comparing once-weekly SHR-3167 with once-daily insulin degludec over up to 33 weeks.
Source: ClinicalTrials.gov registry record, November 3, 2026
-
Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL
Results for the EPCORE DLBCL-1 study were first posted on ClinicalTrials.gov on November 3, 2026. The randomized, open-label Phase 3 trial enrolled 483 participants and compared subcutaneous epcoritamab with investigator's choice chemotherapy (R-GemOx or BR) in relapsed/refractory diffuse large B-cell lymphoma.
Source: ClinicalTrials.gov results record, November 3, 2026
-
Apnimed posts results of Phase 3 AD109 trial in obstructive sleep apnea
The study, enrolling 660 participants, compared AD109 to placebo over 1 year and was completed with primary data posted on November 3, 2026. It began on August 28, 2023 and reached primary completion on May 7, 2025.
Source: ClinicalTrials.gov results record, November 3, 2026
-
Johnson & Johnson Consumer posts results of Phase 3 dental pain study
The study, completed in May 2024, enrolled 447 participants and compared a fixed combination of acetaminophen/naproxen sodium with acetaminophen, naproxen sodium, and placebo for postoperative dental pain. Results were first posted on ClinicalTrials.gov on November 3, 2026.
Source: ClinicalTrials.gov results record, November 3, 2026
-
Povorcitinib meets primary endpoint in two phase 3 vitiligo trials
The authors reported that povorcitinib 30 mg daily achieved ≥75% improvement in facial Vitiligo Area Scoring Index at week 52 in both STOP-V1 and STOP-V2, with 18.9% versus 6.8% and 18.9% versus 3.1% respectively. Treatment-emergent adverse events were similar to placebo, with 68.7%/66.7% versus 63.7%/62.7% and no class-specific serious events.
Source: PubMed record of a Phase III journal article, November 3, 2026
Policy · 2
-
Samsung Biologics achieves 'Negligible Risk' rating in Sustainalytics ESG assessment
Samsung Biologics received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. The result places the company among the top 0.5% of companies assessed in the pharmaceuticals industry.
Source: Company press release (PR Newswire), November 3, 2026
-
Waters acquires MOBILion Systems, adding advanced ion-mobility to its mass spectrometry portfolio
Waters Corporation announced on November 3, 2026 that it has acquired MOBILion Systems, Inc., a pioneer of SLIM high-resolution ion mobility separation technology. The acquisition broadens Waters' entry into the proteomics market, pairing SLIM's separation power with Waters' XevoTM MRT MS speed and resolution enabling superior bottom-up analysis of complex proteomes versus LC-MS alone.
Source: Company press release (PR Newswire), November 3, 2026
Regulation · 2
-
FDA releases final guidance on reducing transfusion-transmitted Hepatitis B virus
FDA announces availability of the final guidance titled "Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus" on November 3, 2026. The guidance supersedes several earlier documents and applies to the collection of Whole Blood and blood components, including Source Plasma.
Source: Federal Register notice, November 3, 2026
-
FDA releases final guidance on potency assurance for cellular and gene therapy products
The notice, published November 3, 2026, announces the availability of the guidance with docket number FDA-2023-D-4299. It recommends a comprehensive strategy grounded in quality risk management for both investigational and licensed CGT products.
Source: Federal Register notice, November 3, 2026